Equibles does not estimate personal net worth.
Get an email with a short summary when Relay Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get RLAY alertsThe proxy statement of Relay Therapeutics, Inc. reports total compensation of $6,613,397 for Donald Bergstrom in fiscal 2024, including a base salary of $543,375. Disclosed compensation is on record for 6 fiscal years. Donald Bergstrom has spoken on 5 investor events across 1 company, most recently for Relay Therapeutics, Inc. on September 16, 2026. Relay Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Relay Therapeutics, Inc. includes Thomas Catinazzo (CFO), Brian R. Adams (General Counsel), Claire Mazumdar (Board Member) and 4 others.
“Yeah, so it's a one-to-one randomized trial of Fulvestrin plus Zavega versus Fulvestrin plus Capiviceratib. The patients who were enrolling have all previously been treated with endocrine therapy and the CDK4-6 inhibitor.”
“Vascular anomalies is an umbrella term for a variety of conditions with a wide range of clinical presentations. There are many separately named syndromes and conditions that fall into this category.”
“Vascular anomalies is an umbrella term for a variety of conditions with a wide range of clinical presentations. There are many separately named syndromes and conditions that fall into this category.”
“We initiated dose finding of Zovega combined with Etermo and standard dose fulvestrins. We did observe an effect of Etermocyclob on blood concentrations of zovegalicin.”
“We initiated dose finding of Zovega combined with Etermo and standard dose fulvestrins. We did observe an effect of Etermocyclob on blood concentrations of zovegalicin.”
Proxy statement
Start not stated–present
Last confirmed April 28, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Relay Therapeutics, Inc. (RLAY) | M.D., Ph.D. President, Research & Development | $543,375 | $6,613,397 |
| 2023 | Relay Therapeutics, Inc. (RLAY) | M.D., Ph.D. President, Research & Development | $525,000 | $8,573,063 |
| 2022 | Relay Therapeutics, Inc. (RLAY) | M.D., Ph.D. President, Research & Development | $500,000 | $3,783,338 |
| 2021 | Relay Therapeutics, Inc. (RLAY) | M.D., Ph.D. President, Research & Development | $475,000 | $3,539,792 |
| 2020 | Relay Therapeutics, Inc. (RLAY) | M.D., Ph.D. President, Research & Development | $440,000 | $1,105,092 |
| 2019 | Relay Therapeutics, Inc. (RLAY) | President, Research & Development | $406,850 | $916,516 |
